A newly FDA-cleared treatment for post-traumatic stress disorder has reported a 68% remission rate in its clinical trial — a figure researchers describe as a quantum leap over existing options. The system, developed by California-based Wave Neuroscience in collaboration with Texas A&M Health, uses an electroencephalogram to record each patient's unique brainwave signature, then feeds that data into an AI-assisted platform that personalises a course of transcranial magnetic stimulation aimed at the specific neural regions disrupted by trauma.

Trial participants underwent five sessions per week for five to six weeks. Beyond the 68% remission figure, patients also experienced an average 52% reduction in symptom severity — more than four times the improvement seen in previous medication studies, where remission rates peaked at just 10.9%. The full trial data is still being prepared for publication, and researchers caution that cross-study comparisons should be made carefully, but the preliminary signals are striking enough to have attracted significant clinical attention.

The development is particularly significant for veterans, among whom roughly 7% receive a PTSD diagnosis each year, and for the approximately 17.5 veterans who die by suicide every day in the United States. Current first-line treatments — SSRIs and cognitive processing therapy — leave a substantial proportion of patients without adequate relief. An FDA Breakthrough Device designation in 2024 allowed the MeRT system to move through regulatory review on an expedited timeline, from trial launch to clearance in just over two years.